Clinical Trial Investigating the Efficacy of the Supera Peripheral Stent System for the Treatment of the Common Femoral Artery

Inclusion Criteria: * Patient presenting a score from 2 to 4 following Rutherford classification * Patient is willing to comply with specified follow-up evaluations at the specified times * Patient is \>18 years old * Patient understands the nature of the procedure and provides written informed consent, prior to enrolment in the study * Patient has a projected life expectancy of at least 12 months * Prior to enrolment, the guidewire has crossed target lesion * De novo lesions located in the common femoral artery, suitable for endovascular therapy * The target lesions are located within the native CFA: localized between the origin of the circumflex iliac artery and the proximal (1cm) superficial femoral artery. * There is angiographic evidence of a patent deep femoral artery * The target lesion has angiographic evidence of stenosis \> 50% or occlusion * There is angiographic evidence of at least one-vessel-runoff to the foot, irrespective of whether or not outflow was re-established by means of previous endovascular intervention Exclusion Criteria: * Presence of another stent in the target vessel that was placed during a previous procedure * Previous open surgery in the same limb * Patients contraindicated for antiplatelet therapy, anticoagulants or thrombolytics. * Patients who exhibit persistent acute intraluminal thrombus at the target lesion site. * Perforation at the angioplasty site evidenced by extravasation of contrast medium * Patients with known hypersensitivity to nickel-titanium and heparin, including those patients who have had a previous incidence of heparin-induced thrombocytopenia (HIT) type II * Patients with uncorrected bleeding disorders * Female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding * Ipsilateral inflow (aorto-iliac) artery treatment before target lesion treatment with a residual stenosis\>30% * Use of thrombectomy, atherectomy or laser devices during procedure * Any planned surgical intervention/procedure 30 days after the study procedure * Any patient considered to be hemodynamically unstable at onset of procedure * Patient is currently participating in another investigational drug or device study that has not reached the primary endpoint. * Severe medical comorbidities (untreated CAD/CHF, severe COPD, metastatic malignancy, dementia, etc.) or other medical condition that would preclude compliance with the study protocol or 1-year life expectancy * Major distal amputation (above the transmetatarsal) in the study limb or non-study limb * Septicemia or bacteremia * Known allergy to contrast media that cannot be adequately pre-medicated prior to the study procedure